This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Osta, W. A. Articles by Gillanders, W. E. Search for Related Content PubMed PubMed Citation Articles by Osta, W. A. Articles by Gillanders, W. E.

EpCAM Is Overexpressed in Breast Cancer and Is a Potential Target for Breast Cancer Gene Therapy

Departments of ¹ Surgery and ² Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina

EpCAM (epithelial cell adhesion molecule) is a cell surface molecule that is known to be highly expressed in colon and other epithelial carcinomas. EpCAM is involved in cell-to-cell adhesion and has been the target of antibody therapy in several clinical trials. To assess the value of EpCAM as a novel target for breast cancer gene therapy, we performed real-time reverse transcription-PCR to quantify the level of EpCAM mRNA expression in normal breast tissue and primary and metastatic breast cancers. We found that EpCAM is overexpressed 100- to 1000-fold in primary and metastatic breast cancer. Silencing EpCAM gene expression with EpCAM short interfering RNA (siRNA) resulted in a 35–80% decrease in the rate of cell proliferation in four different breast cancer cell lines. EpCAM siRNA treatment decreased cell migration by 91.8% and cell invasion by 96.4% in the breast cancer cell line MDA-MB-231 in vitro. EpCAM siRNA treatment was also associated with an increase in the detergent-insoluble protein fraction of E-cadherin, -catenin, and ß-catenin, consistent with the known biology of EpCAM as a regulator of cell adhesion. Our hypothesis is that modulation of EpCAM expression can affect cell migration, invasion, and proliferation by enhancing E-cadherin-mediated cell-to-cell adhesion. These data provide compelling evidence that EpCAM is a potential novel target for breast cancer gene therapy and offer insights into the mechanisms associated with EpCAM gene silencing.

This article has been cited by other articles:

				Y. KIM, H. S. KIM, Z. Y. CUI, H.-S. LEE, J. S. AHN, C. K. PARK, K. PARK, and M.-J. AHN Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung Anticancer Res, May 1, 2009; 29(5): 1817 - 1822. [Abstract] [Full Text] [PDF]

				T. Nubel, J. Preobraschenski, H. Tuncay, T. Weiss, S. Kuhn, M. Ladwein, L. Langbein, and M. Zoller Claudin-7 Regulates EpCAM-Mediated Functions in Tumor Progression Mol. Cancer Res., March 1, 2009; 7(3): 285 - 299. [Abstract] [Full Text] [PDF]

				N. V. Sankpal, M. W. Willman, T. P. Fleming, J. D. Mayfield, and W. E. Gillanders Transcriptional Repression of Epithelial Cell Adhesion Molecule Contributes to p53 Control of Breast Cancer Invasion Cancer Res., February 1, 2009; 69(3): 753 - 757. [Abstract] [Full Text] [PDF]

				M.-R. Pan, H.-C. Chang, Y.-C. Wu, C.-C. Huang, and W.-C. Hung Tubocapsanolide A Inhibits Transforming Growth Factor-{beta}-activating Kinase 1 to Suppress NF-{kappa}B-induced CCR7 J. Biol. Chem., January 30, 2009; 284(5): 2746 - 2754. [Abstract] [Full Text] [PDF]

				P. Bhat-Nakshatri, G. Wang, H. Appaiah, N. Luktuke, J. S. Carroll, T. R. Geistlinger, M. Brown, S. Badve, Y. Liu, and H. Nakshatri AKT Alters Genome-Wide Estrogen Receptor {alpha} Binding and Impacts Estrogen Signaling in Breast Cancer Mol. Cell. Biol., December 15, 2008; 28(24): 7487 - 7503. [Abstract] [Full Text] [PDF]

				M. Schmidt, D. Hasenclever, M. Schaeffer, D. Boehm, C. Cotarelo, E. Steiner, A. Lebrecht, W. Siggelkow, W. Weikel, I. Schiffer-Petry, et al. Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer Clin. Cancer Res., September 15, 2008; 14(18): 5849 - 5855. [Abstract] [Full Text] [PDF]

				A Brunner, M Prelog, I Verdorfer, A Tzankov, G Mikuz, and C Ensinger EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder J. Clin. Pathol., March 1, 2008; 61(3): 307 - 310. [Abstract] [Full Text] [PDF]

				M. Amann, K. Brischwein, P. Lutterbuese, L. Parr, L. Petersen, G. Lorenczewski, E. Krinner, S. Bruckmeier, S. Lippold, R. Kischel, et al. Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3 Cancer Res., January 1, 2008; 68(1): 143 - 151. [Abstract] [Full Text] [PDF]

				D Fong, M Steurer, P Obrist, V Barbieri, R Margreiter, A Amberger, K Laimer, G Gastl, A Tzankov, and G Spizzo Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance J. Clin. Pathol., January 1, 2008; 61(1): 31 - 35. [Abstract] [Full Text] [PDF]

				T. Yamashita, A. Budhu, M. Forgues, and X. W. Wang Activation of Hepatic Stem Cell Marker EpCAM by Wnt {beta}-Catenin Signaling in Hepatocellular Carcinoma Cancer Res., November 15, 2007; 67(22): 10831 - 10839. [Abstract] [Full Text] [PDF]

				M. Trzpis, P. M.J. McLaughlin, L. M.F.H. de Leij, and M. C. Harmsen Epithelial Cell Adhesion Molecule: More than a Carcinoma Marker and Adhesion Molecule Am. J. Pathol., August 1, 2007; 171(2): 386 - 395. [Abstract] [Full Text] [PDF]

				G. W. Sledge Jr. Circulating tumor cells in breast cancer: blood will tell. Clin. Cancer Res., November 1, 2006; 12(21): 6321 - 6322. [Full Text] [PDF]

				F. Le Naour, M. Andre, C. Greco, M. Billard, B. Sordat, J.-F. Emile, F. Lanza, C. Boucheix, and E. Rubinstein Profiling of the Tetraspanin Web of Human Colon Cancer Cells Mol. Cell. Proteomics, May 1, 2006; 5(5): 845 - 857. [Abstract] [Full Text] [PDF]

				K. Mikhitarian, W. E. Gillanders, J. S. Almeida, R. Hebert Martin, J. C. Varela, J. S. Metcalf, D. J. Cole, and M. Mitas An Innovative Microarray Strategy Identities Informative Molecular Markers for the Detection of Micrometastatic Breast Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3697 - 3704. [Abstract] [Full Text] [PDF]